A Phase III Pivotal, Multicenter, Double-Blind, Randomized, Placebo-Controlled Monotherapy Study of Milnacipran for the Treatment of Fibromyalgia.

Trial Profile

A Phase III Pivotal, Multicenter, Double-Blind, Randomized, Placebo-Controlled Monotherapy Study of Milnacipran for the Treatment of Fibromyalgia.

Completed
Phase of Trial: Phase III

Latest Information Update: 19 Mar 2012

At a glance

  • Drugs Milnacipran (Primary)
  • Indications Fibromyalgia
  • Focus Registrational; Therapeutic Use
  • Sponsors Forest Laboratories
  • Most Recent Events

    • 02 Sep 2010 Results regarding the impact of abrupt drug withdrawal were reported at the 13th World Congress on Pain.
    • 02 Sep 2010 Results were reported at the 13th World Congress on Pain.
    • 16 Jun 2010 Results pertaining to the impact of abrupt drug withdrawal have been presented at 11th Annual Congress of the European League Against Rheumatism (EULAR) 2010
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top